The Challenges for the US of Regulating Compliance and Quality on a Global Scale
This article was originally published in SRA
Bob Rhoadesdiscusses the problems faced by US regulators and industry in ensuring the safety of imported devices and device components manufactured overseas.
You may also be interested in...
UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.
Janssen and AstraZeneca are among a raft of companies that might this week find out whether the European Medicines Agency will recommend approval of their products for expanded therapeutic indications.
Shares in Iovance Biotherapeutics have soared this week amid reports the US clinical-stage biotechnology company is in active M&A talks.